Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor

Trial Profile

Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Furosemide (Primary) ; Furosemide
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOM-HF
  • Sponsors scPharmaceuticals
  • Most Recent Events

    • 10 Aug 2023 According to scPharmaceuticals Media Release, the company announced that results from the FREEDOM-HF study have been accepted for publication in the peer-reviewed journal Future Cardiology.
    • 10 May 2023 According to a scPharmaceuticals media release, data from this study were presented at the Technology and Heart Failure Therapeutics Conference 2023.
    • 22 Mar 2023 According to a scPharmaceuticals media release, data from this study will be presented at the Technology and Heart Failure Therapeutics Conference, March 20-22, 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top